中华肝脏病杂志最新文献

In recent years, minimally invasive surgical techniques, especially laparoscopic and robot-assisted surgery, have fundamentally changed the standard procedure for living donor liver retrieval and are gradually expanding into the core area of recipient surgery. This review systematically examines the latest advancements in the application of minimally invasive techniques in surgery for liver transplant recipients, focusing on the current status of the integrated application of innovative technologies such as laparoscopy, robot-assisted surgery, and magnetic anastomosis. In addition, this article delves into the potential and evidence-based basis for improving postoperative recovery and reducing surgical complications, and analyze the technical complexity, ethical considerations, equipment dependence, and training challenges faced in achieving full minimally invasiveness in key stages of donor liver implantation. Lastly, the future development directions are discussed, emphasizing that innovation in technological instruments, establishment of standardized training systems, deep multidisciplinary integration, and assemblage with emerging technologies are key pathways to safely and efficiently advance this field, ultimately aiming to provide optimized surgical treatment options for more patients with end-stage liver disease.

Massive hepatic necrosis (MHN) is defined as hepatocyte death exceeding 70% in the entire liver. Acute liver failure induced by MHN can lead to death in nearly half of patients. However, the vast majority of lost hepatocyte conditions can recover in about half of these patients. Hepatocyte function restoration and gradual differentiation into mature hepatocytes primarily rely on the rapid activation and proliferation of liver progenitor cells (LPCs) in these survived patients. This paper mainly describes the cellular and molecular mechanisms by which LPCs restore liver function and rescue patients following the occurrence of MHN.

Objective: To evaluate the safety and efficacy of using small and ultra-small sized grafts for in situ auxiliary liver transplantation in the treatment of portal hypertension. Methods: A prospective single-arm cohort study was conducted. Patients who underwent liver transplantation at Beijing Friendship Hospital from December 2014 to July 2025 were included. Intraoperative portal vein pressure was routinely monitored, with the target regulation for portal vein blood flow set at<15 mmHg (1 mmHg=0.133 kPa) and follow-up continued until September 2025. The primary endpoints were the patient's status and graft survival. The secondary endpoints were small-for-size syndrome and perioperative complications. The small-for-size syndrome was graded according to the 2023 International Liver Transplantation Society consensus statement. Results: A total of 33 cases were enrolled. Among them, 22 had ultra-small size grafts, 11 had small-size grafts, 28 had living donor grafts, and five had split grafts. The graft-to-recipient weight ratio in living donor liver transplantation was 0.31%～0.79%, while in split liver transplantation it was 0.45%～1.02%. Intraoperative portal vein pressure of ≥15 mmHg was observed in 11 cases, who underwent portal vein blood flow adjustment via splenic artery ligation (2 cases), partial splenectomy (8 cases), and/or restrictive portocaval shunting (1 case), after which all patients achieved the target portal vein pressure. All cases completed at least one month of follow-up, with 28 cases following for more than one year, and the median follow-up period was 36.5 months. Early-stage postoperative small-for-size syndrome occurred in eight cases (24.2%, 8/33), all classified as grade A, with improvements following supportive treatment. Severe complications (Clavien-Dindo≥Ⅲ) occurred in three cases (9.1%, 3/33). The one-year survival rate was 92.9% (26/28). The overall survival rate at the end of follow-up was 90.9% (30/33). No patients experienced graft loss or death due to small-for-size syndrome. Graft tissue tested negative for hepatitis B core antibody and covalently closed circular DNA, and hepatitis B surface antigen seroconversion was achieved following second-stage residual liver resection and under a combined strategy of potent nucleos(t)ide analogs and hepatitis B immunoglobulin in ten cases of hepatitis B-related disease. Conclusions: With standardized portal vein blood flow monitoring and individualized portal vein blood flow adjustment, in situ auxiliary liver transplantation can safely and effectively use small and even ultra-small sized grafts, thereby significantly expanding graft sources and ensuring donor and recipient safety. These findings warrant further validation and promotion in multicenter controlled studies.

Liver disease is a major global health issue, severely impacting patients' quality of life and life expectancy. Integrated Traditional Chinese and Western Medicine demonstrates unique advantages in the field of liver disease treatment. Therefore, this article elaborates on the research progress of integrated traditional Chinese and Western medicine in viral hepatitis, metabolic dysfunction-associated steatotic liver disease, cirrhosis, and liver cancer.

Nonalcoholic steatohepatitis (NASH) is a chronic liver disease associated with metabolic syndrome, such as obesity, diabetes, and hyperlipidemia, and is a progressive form of nonalcoholic fatty liver disease with pathological features including steatosis, lobular inflammation, and hepatocyte damage (ballooning degeneration). Hepatocellular ballooning degeneration is an important pathological feature of NASH and is closely related to the prognosis of NASH patients. Accurate identification of hepatocellular ballooning degeneration is of great significance for diagnosing NASH and assessing therapeutic response. This article reviews the current status and identification methods of hepatocellular ballooning degeneration in NASH, including invasive and noninvasive.

Wilson disease (WD), also known as hepatolenticular degeneration, is an autosomal recessive inherited disorder of copper metabolism that primarily affects the liver, brain, and other organs. The diagnostic criteria include clinical features, biochemical tests (plasma ceruloplasmin, 24-hour urinary copper, liver copper content), and molecular genetic analysis. The Leipzig scoring system, supplemented by the use of exchangeable copper, is recommended for diagnosis. Pharmacotherapy mainly includes chelating agents (such as penicillamine and trientine) and zinc salts. Chelating agent therapy is recommended only for patients with severe liver disease. Patient monitoring is primarily based on clinical symptoms, liver biochemical indices, and copper metabolism parameters (such as 24-hour urinary copper and exchangeable copper) to identify poor adherence as well as over-treatment or under-treatment situations. The diagnosis and treatment of acute liver failure with WD is extremely challenging, as the diagnosis is difficult and medical treatment cannot save life. The role of liver transplantation has been clearly recognized in the treatment of acute liver failure with WD, and it may also be considered in cases with neurological involvement.

Portal hypertension is a major complication of cirrhosis. The current gold standard for diagnosis is the hepatic venous pressure gradient, but it possesses limitations such as invasiveness. In recent years, non-invasive tests have made significant progress in terms of evaluating and prognostication of portal hypertension. This article reviews the diagnostic value and related research advancements of different non-invasive tests in assessing portal hypertension in patients with cirrhosis.

Liver injury, as one of the common clinical manifestations of brucellosis, presents a diversity of pathophysiological mechanisms, pathological manifestations, and clinical features, which may trigger severe organ dysfunction and poor prognostic conditions. This article systematically analyzes the research progress on brucellosis combined with liver injury at home and abroad, focusing on discussing its pathophysiological mechanism, pathological and clinical features, as well as prognostic outcomes, with the aim to provide a solid theoretical basis for the clinical diagnosis, therapeutic strategies, and prognostic management.

Liver fibrosis is a common pathological process in various chronic liver diseases. Early-stage and accurate diagnosis, as well as assessment of the degree of liver fibrosis, is crucial for the management of chronic liver diseases. Conventional imaging techniques for liver fibrosis (elastography and magnetic resonance elastography) still have the drawback of low sensitivity in detecting early-stage fibrosis. In recent years, emerging imaging omics based on ultrasound and magnetic resonance have improved the diagnostic accuracy and visualization stage of liver fibrosis. The emergence of artificial intelligence technology has also provided more options for the technological advancement of liver fibrosis imaging. This article aims to review the emerging liver fibrosis imaging technologies in recent years and compare their diagnostic performance with ultrasound elastography, shear wave elastography, and magnetic resonance elastography recommended by the current domestic and international guidelines and to pinpoint simultaneously the limitations and challenges that still exist in liver fibrosis imaging while reflecting the technological advances.